clinical trial · NCT07594158
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Ono Pharmaceutical Co., Ltd.·phase3·recruiting·n = 20
Partial EpilepsyCenobamate (tablet) for 12 to < 18 year oldsCenobamate (syrup) for 2 to < 18 year olds
brief summary
Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures
started
May 30, 2026
primary completion
Mar 30, 2028
completion
Dec 31, 2029
last updated
May 18, 2026
detailed description
Secondary objectives:
To evaluate the efficacy of cenobamate tablets and suspension in Japanese pediatric subjects with partial onset (focal) seizures
To evaluate the pharmacokinetics of cenobamate tablets and suspension in Japanese pediatric subjects with partial onset seizures
official title
A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ONO-2017 in Japanese Patients With Partial Onset Seizures Aged 2 to Under 18 Years.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol